The U.S. National Institutes of Health (NIH) awarded seven companies and academic institutions grants to develop digital health technology to help with the Covid-19 pandemic.
According to a new study by Worldwide Partners, the effect that Covid-19 is having on digital health adoption is set to be transformative. The survey that was conducted shows technology is playing a crucial and growing role in mitigating the healthcare crisis, especially via telehealth.
Faster Drug Development Processes Likely to Outlive COVID-19 Published: April 30, 2020 By Gail Dutton BioSpace The COVID-19 pandemic has increased the pace of drug development and regulatory approval dramatically, accelerating activities in ways that shorten the time needed to deliver safe, effective therapeutics, vaccines and diagnostics to patients. “It’s unfortunate it took a […]
As the J.P. Morgan Healthcare Conference entered the final day for 2020, a few topics rose to the top as trending, including the relative lack of big deals.
Over the last few years, there has appeared to be big interest on the part of biopharma in leveraging artificial intelligence (AI) and machine learning to improve trial design and speed up drug development. Another related category is digital therapeutics (DTx), which the Digital Therapeutics Alliance says, “deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage or treat a broad spectrum of physical, mental and behavioral conditions.”
Accelmed, a U.S.-Israel group of funds investing in medical device and digital health companies, is establishing a new fund with the aim of raising and managing $100 million.
Drugmaker Eli Lilly and Company said early results from a study suggest that Apple Inc. devices, including the iPhone, in combination with digital apps could differentiate people with mild Alzheimer’s disease dementia and those without symptoms.
Israel’s Pitango Venture Capital is launching a fund that will reach $150 million to invest in health technology.
Abbott and Novo Nordisk announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with Abbott’s FreeStyle Libre system (FreeStyle LibreLinkii mobile app and LibreViewiii cloud-based system).
Evidenced by the move to measure and reimburse providers based on the quality, as opposed to the quantity, of care delivered, the healthcare industry is shifting from a fee-for-service to an outcomes or value-based model.